ALK and adenocarcinoma: An overall view of the mutational status of the 230 adenocarcinoma patients showed that 62% of them display activating mutations in known driver oncogenes (such as EGFR, KRES, BRAF mutations, ALK, ROS1 and RET fusions), the remaining 38% of patients was without any apparent RTK/RAS/RAF oncogene mutation.